PMID- 23725150
OWN - NLM
STAT- MEDLINE
DCOM- 20131022
LR  - 20190606
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 14
IP  - 4
DP  - 2013
TI  - Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as 
      maintenance therapy for advanced non- small-cell lung cancer: a meta-analysis of 
      randomized controlled trials.
PG  - 2413-9
AB  - BACKGROUND: Use of epidermal growth factor receptor inhibitors (EGFR-TKIs ) is 
      now standard for non- small-cell lung cancer (NSCLC). However, the effects of 
      EGFR-TKIs in maintenance therapy for advanced NSCLC patients are still unclear. 
      The preent meta-analysis was performed to examine pooled data of randomized 
      control trials (RCT) where EGFR-TKIs were compared against placebo in maintenance 
      regimens for patients with advanced NCSLC to quantify potential benefits and 
      determine safety. METHODS: Several data bases were searched, including PubMed, 
      EMBASE and CENTRAL, and we performed an internet search of conference literature. 
      The endpoints were objective response rates (ORR), progression-free survival 
      (PFS) and overall survival (OS). We performed a meta-analysis of the published 
      data, using Comprehensive Meta Analysis software (Version 2.0). with a fixed 
      effects model and an additional random effects model, when applicable. The 
      results of the meta-analysis are expressed as hazard ratios (HRs) or risk ratios 
      (RRs), with their corresponding 95% confidence intervals (95%CIs). RESULTS: The 
      final analysis included six trials, covering 3,758 patients. Compared with 
      placebo, EGFR-TKIs maintenance therapy improved ORR and PFS for patients with 
      advanced NSCLC, the difference being statistically significant (P<0.05), but 
      proved unable to prolong patients' OS. The main adverse reactions were diarrhea 
      and rashes. CONCLUSION: EGFR-TKIs demonstrated encouraging efficacy, safety and 
      survival when delivered as maintenance therapy for patients with advanced NSCLC 
      after first-line chemotherapy, especially for the patients who had 
      adenocarcinomas, were female, non-smokers and patients with EGFR gene mutations.
FAU - Alimujiang, S
AU  - Alimujiang S
AD  - Department of Chemotherapy, Tumor Hospital Affiliated to Xinjiang Medical 
      University, Urumqi, China.
FAU - Zhang, Tao
AU  - Zhang T
FAU - Han, Zhi-Gang
AU  - Han ZG
FAU - Yuan, Shuai-Fei
AU  - Yuan SF
FAU - Wang, Qiang
AU  - Wang Q
FAU - Yu, Ting-Ting
AU  - Yu TT
FAU - Shan, Li
AU  - Shan L
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Prognosis
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Randomized Controlled Trials as Topic
EDAT- 2013/06/04 06:00
MHDA- 2013/10/23 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/06/04 06:00 [entrez]
PHST- 2013/06/04 06:00 [pubmed]
PHST- 2013/10/23 06:00 [medline]
AID - 10.7314/apjcp.2013.14.4.2413 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2013;14(4):2413-9. doi: 10.7314/apjcp.2013.14.4.2413.